Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Hematology

What Is the Difference Between EHL and SHL Factor?

At a Glance

Extended half-life (EHL) factor stays active in the bloodstream longer than standard half-life (SHL) factor, so some people with hemophilia can infuse less often. The best product and dose depend on hemophilia type, the medicine, how quickly the body removes factor, and bleed protection needs.

In this answer

4 sections

01

How Extended Half-Life Factor Works

02

The Difference Between Hemophilia A and Hemophilia B

03

The Role of Pharmacokinetic (PK) Testing

04

Important Safety and Switching Considerations

The main difference between standard half-life (SHL) and extended half-life (EHL) factor is how long the medication remains active in your bloodstream. EHL products are manufactured with molecular changes designed to slow down how quickly your body clears the factor, which can allow you to go longer between infusions [1][2]. Depending on your specific type of hemophilia (A or B) and the exact product used, switching from an SHL to an EHL factor might reduce your infusion schedule [3][4]. For many people, this transition relieves “infusion fatigue” and lessens the burden of frequent needle sticks [5][6].

However, EHL and SHL products are not interchangeable dose-for-dose, and an EHL product will not automatically eliminate all bleeds [7][8]. Never change your factor product, dose, or infusion interval on your own. Any switch must be carefully prescribed and monitored by your hemophilia treatment center.

How Extended Half-Life Factor Works

Your body naturally clears factor proteins from the blood over time. “Half-life” refers to the time it takes for half of the infused factor to be cleared from your circulation. EHL products use scientific modifications to delay this clearing process:

  • PEGylation: This process attaches a substance called PEG (polyethylene glycol) to the factor protein. This creates a protective, water-attracting “cloud” that may reduce the factor’s susceptibility to being broken down by enzymes or cleared by cellular receptors [1][9].
  • Fc-Fusion and Albumin Fusion: These techniques attach either albumin or the “Fc” portion of an IgG antibody to the factor [2][9]. Your body has natural receptors (called neonatal Fc receptors, or FcRn) that normally protect these specific proteins from destruction. When the factor is attached to them, it gets recycled back into the bloodstream rather than being broken down [2][9].

The Difference Between Hemophilia A and Hemophilia B

The amount of extra time you can gain between infusions depends heavily on whether you have Hemophilia A (Factor VIII) or Hemophilia B (Factor IX), as well as the specific product your doctor prescribes.

  • Hemophilia A (Factor VIII): For conventional EHL Factor VIII products, the half-life is typically extended by about 1.5 to 2 times compared to standard products [10][11]. This is because Factor VIII must attach to another protein in the blood called von Willebrand factor (VWF) to survive. VWF has its own natural half-life, which creates a “ceiling” on how long these conventional modified Factor VIII products can last [10][11]. While SHL Factor VIII often requires infusing about three times a week, conventional EHL Factor VIII may allow for twice-weekly dosing [3][4]. However, newer engineered products (like efanesoctocog alfa) are designed to overcome this VWF limitation, making once-weekly dosing possible for some patients [12][13][14].
  • Hemophilia B (Factor IX): Factor IX is not limited by VWF, so EHL modifications result in much larger gains—often extending the half-life by 3 to 5 times compared to SHL products [3][15]. While SHL Factor IX is commonly infused at least twice weekly, EHL Factor IX often permits weekly or every 1-to-2-week dosing [3][16]. Some specific regimens have been given every 14 to 21 days, though this is product-dependent and not a routine starting schedule for everyone [16].

The Role of Pharmacokinetic (PK) Testing

If you are considering a switch, your care team may use Pharmacokinetic (PK) testing or modeling. PK testing estimates how your unique body clears the factor over time, which helps your doctor individualize your dose rather than relying on average label schedules [17][18].

Everyone’s metabolism is different. Your personal half-life can be influenced by your age, body size, and blood type [19][20]. For example, people with blood type O generally clear Factor VIII faster, which may result in a shorter half-life [19][21]. Because of these differences, the benefits of switching to an EHL product vary. In one study of patients switching to EHL, nearly all patients with Hemophilia B gained a clinically relevant extension in half-life, but 40% of patients with Hemophilia A saw only limited extension or a decrease [22].

(Note: Your physical activity level does not change how fast your body clears the factor, but a highly active lifestyle may mean you require a higher “trough”—the lowest level of factor in your blood just before the next dose—to stay protected from bleeds [23].)

Important Safety and Switching Considerations

Switching to an EHL product can significantly lessen the treatment burden, which can be an advantage for children with difficult venous access or adults experiencing infusion burnout [6][24]. In many real-world comparisons, switching maintained or improved bleed prevention [25][26]. However, a reduction in infusions does not necessarily mean you will use less total factor, and EHL products can sometimes be more expensive [26][22][27].

If you and your doctor decide to switch, keep these safety points in mind:

  • Special Populations: The general expectations for EHL products apply mainly to patients with congenital hemophilia who do not have inhibitors (antibodies that destroy the factor). If you have a history of inhibitors, or if you are using a non-factor therapy (like emicizumab), your treatment choices and monitoring will be different [19][21][28].
  • Acute Bleeds and Emergencies: Prophylaxis (preventative) dosing is different from treatment dosing. Always ask your team for a written plan. If you suspect a joint or muscle bleed, sustain a head injury, or have an upcoming surgery or dental procedure, contact your hemophilia treatment center immediately [17][29]. Do not wait for your next scheduled EHL dose to seek treatment.

Common questions in this guide

What is the main difference between EHL and SHL factor?
EHL, or extended half-life, factor is designed to stay in the bloodstream longer, while SHL, or standard half-life, factor is removed more quickly. This may allow longer intervals between EHL infusions, but the schedule depends on the product and your type of hemophilia. EHL and SHL doses are not interchangeable.
How much less often might I need factor infusions with EHL?
For hemophilia A, conventional EHL factor VIII often supports twice-weekly dosing instead of about three SHL infusions per week, while newer products may allow once-weekly dosing for some people. For hemophilia B, EHL factor IX may support weekly or every-one-to-two-week dosing compared with at least twice-weekly SHL dosing. The exact schedule is specific to the product and patient.
Does switching to EHL factor mean I will not have any more bleeds?
No. EHL may maintain factor levels longer and reduce the burden of treatment, but it does not eliminate every breakthrough bleed. Contact your hemophilia treatment center promptly for a suspected joint or muscle bleed, head injury, or planned surgery or dental procedure.
What is PK testing, and why might I need it before switching to EHL?
Pharmacokinetic, or PK, testing estimates how quickly your body removes factor after an infusion. The results can help your hemophilia team choose a dose and interval based on your personal response rather than an average schedule. Age, body size, and blood type, including type O for factor VIII, can affect the result.
Can I change from SHL to EHL without changing my dose?
No. EHL and SHL products are not dose-for-dose interchangeable, and the dose for preventing bleeds differs from the dose used to treat an acute bleed. Any switch should be prescribed and monitored by your hemophilia treatment center, with a written plan for breakthrough bleeds.
Will fewer EHL infusions reduce how much factor I use or lower treatment costs?
Not necessarily. Fewer needle sticks can reduce treatment burden, but total factor use may not decrease, and EHL products can sometimes cost more. Your care team can compare the expected protection, dosing schedule, and overall treatment burden for your situation.

Related questions

What Sports Are Safe for Children With Hemophilia? How Are Hemophilia Inhibitors Treated and Eradicated? What Are the Subcutaneous Treatments for Hemophilia? What Pain Medicines Are Safer for Hemophilia Joint Damage? Who Is Eligible for Roctavian or Hemgenix Gene Therapy?
Show more
Can I Take Blood Thinners for Heart Disease With Hemophilia? Does Mild Hemophilia Need Prophylaxis or On-Demand Therapy? Do Hemophilia Patients Need Factor Before Dental Work? How Can Hemophilia Patients Prevent Osteoporosis Safely? How to Transition a Teen With Hemophilia to Adult Care Can Female Hemophilia Carriers Bleed and Pass On the Gene? What Are Brain Bleed Signs in a Toddler with Hemophilia? What Does an Early Hemophilia Joint Bleed Feel Like? Can a Baby With Hemophilia Have a Normal Life Expectancy?

Get notified when new evidence is published on Hemophilia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (29)
  1. 1

    Potential role of a new PEGylated recombinant factor VIII for hemophilia A.

    Wynn TT, Gumuscu B

    Journal of blood medicine 2016; (7()):121-8 doi:10.2147/JBM.S82457.

    PMID: 27382347
  2. 2

    New developments in the management of moderate-to-severe hemophilia B.

    Nazeef M, Sheehan JP

    Journal of blood medicine 2016; (7()):27-38 doi:10.2147/JBM.S81520.

    PMID: 27099538
  3. 3

    Practical aspects of extended half-life products for the treatment of haemophilia.

    Lambert T, Benson G, Dolan G, et al.

    Therapeutic advances in hematology 2018; (9(9)):295-308 doi:10.1177/2040620718796429.

    PMID: 30210757
  4. 4

    Extended half-life clotting factor concentrates: results from published clinical trials.

    Young G, Mahlangu JN

    Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22 Suppl 5()):25-30 doi:10.1111/hae.13028.

    PMID: 27405672
  5. 5

    Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

    Tagliaferri A, Matichecchia A, Rivolta GF, et al.

    Blood transfusion = Trasfusione del sangue 2020; (18(5)):374-385 doi:10.2450/2019.0220-19.

    PMID: 31855153
  6. 6

    The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States.

    Malec LM, Cheng D, Witmer CM, et al.

    American journal of hematology 2020; (95(8)):960-965 doi:10.1002/ajh.25844.

    PMID: 32356313
  7. 7

    Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.

    Kitchen S, Tiefenbacher S, Gosselin R

    Seminars in thrombosis and hemostasis 2017; (43(3)):331-337 doi:10.1055/s-0037-1598058.

    PMID: 28264199
  8. 8

    In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.

    Preijers T, Bukkems L, van Spengler M, et al.

    European journal of clinical pharmacology 2021; (77(8)):1193-1200 doi:10.1007/s00228-021-03111-2.

    PMID: 33624121
  9. 9

    Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.

    Chia J, Louber J, Glauser I, et al.

    The Journal of biological chemistry 2018; (293(17)):6363-6373 doi:10.1074/jbc.M117.817064.

    PMID: 29523681
  10. 10

    Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

    Pipe SW, Montgomery RR, Pratt KP, et al.

    Blood 2016; (128(16)):2007-2016 doi:10.1182/blood-2016-04-713289.

    PMID: 27587878
  11. 11

    Extended Half-Life Factor VIII and Factor IX Preparations.

    Graf L

    Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2018; (45(2)):86-91 doi:10.1159/000488060.

    PMID: 29765290
  12. 12

    SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.

    Tiede A, Allen G, Bauer A, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2020; (26(1)):47-55 doi:10.1111/hae.13878.

    PMID: 31778283
  13. 13

    BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.

    Konkle BA, Shapiro AD, Quon DV, et al.

    The New England journal of medicine 2020; (383(11)):1018-1027 doi:10.1056/NEJMoa2002699.

    PMID: 32905674
  14. 14

    Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis.

    Susen S, Kulkarni R, Nogami K, et al.

    Therapeutic advances in hematology 2026; (17()):20406207251398986 doi:10.1177/20406207251398986.

    PMID: 41583536
  15. 15

    Clinical application of extended half-life factor VIII in children with severe haemophilia A.

    Dettoraki A, Michalopoulou A, Mazarakis M, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28(4)):619-624 doi:10.1111/hae.14576.

    PMID: 35503081
  16. 16

    IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data.

    Escobar M, Mancuso ME, Hermans C, et al.

    Journal of clinical medicine 2022; (11(4)) doi:10.3390/jcm11041071.

    PMID: 35207344
  17. 17

    Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.

    Preijers T, Schütte LM, Kruip MJHA, et al.

    Therapeutic drug monitoring 2019; (41(2)):192-212 doi:10.1097/FTD.0000000000000625.

    PMID: 30883513
  18. 18

    Using pharmacokinetics to individualize hemophilia therapy.

    Iorio A

    Hematology. American Society of Hematology. Education Program 2017; (2017(1)):595-604 doi:10.1182/asheducation-2017.1.595.

    PMID: 29222309
  19. 19

    Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.

    Versloot O, Iserman E, Chelle P, et al.

    Journal of thrombosis and haemostasis : JTH 2021; (19(8)):1896-1906 doi:10.1111/jth.15395.

    PMID: 34013558
  20. 20

    Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.

    McEneny-King A, Chelle P, Foster G, et al.

    Journal of pharmacokinetics and pharmacodynamics 2019; (46(5)):411-426 doi:10.1007/s10928-019-09634-7.

    PMID: 31104228
  21. 21

    Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.

    Solms A, Iorio A, Ahsman MJ, et al.

    Clinical pharmacokinetics 2020; (59(5)):605-616 doi:10.1007/s40262-019-00832-7.

    PMID: 31749076
  22. 22

    Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia.

    Versloot O, Iserman E, Chelle P, et al.

    HemaSphere 2022; (6(4)):e694 doi:10.1097/HS9.0000000000000694.

    PMID: 35356797
  23. 23

    Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX-FP Prophylaxis in Hemophilia B: A Repeated Time-to-Event Analysis.

    Koopman SF, Cnossen MH, Mathot RAA,

    Clinical pharmacology and therapeutics 2025; (118(4)):831-840 doi:10.1002/cpt.3724.

    PMID: 40386832
  24. 24

    Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.

    Morfini M, Gherardini S

    Therapeutic advances in hematology 2018; (9(6)):149-162 doi:10.1177/2040620718774258.

    PMID: 29899890
  25. 25

    Real-world data of extended half-life factor VIII prophylaxis in patients with hemophilia A: A multicenter retrospective cohort study.

    Demircioğlu S, Karakuş A, Demircan V, et al.

    Thrombosis research 2026; (266()):109871 doi:10.1016/j.thromres.2026.109871.

    PMID: 42901012
  26. 26

    The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.

    Brennan Y, Parikh S, McRae S, Tran H

    Haemophilia : the official journal of the World Federation of Hemophilia 2020; (26(3)):529-535 doi:10.1111/hae.13970.

    PMID: 32243027
  27. 27

    Real-World Analysis of Dispensed International Units of Coagulation Factor VIII and Resultant Expenditures for Hemophilia A Patients: A Comparison Between Standard Half-Life and Extended Half-Life Products.

    Chhabra A, Fogarty PF, Tortella BJ, et al.

    Managed care (Langhorne, Pa.) 2018; (27(10)):39-50.

    PMID: 30309448
  28. 28

    Extended Half-Life Factor Concentrates in Haemophilia Treatment.

    Holstein K, Bajorat T, Beck R, et al.

    Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2026; (53(4)):191-200 doi:10.1159/000551421.

    PMID: 42146127
  29. 29

    In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.

    Preijers T, Hazendonk HCAM, Fijnvandraat K, et al.

    Journal of thrombosis and haemostasis : JTH 2017; (15(9)):1737-1746 doi:10.1111/jth.13771.

    PMID: 28688133

This page explains EHL and SHL factor options for general education and does not replace medical advice. Do not change your factor product, dose, or infusion schedule without guidance from your hemophilia treatment center.